Abstract
Prospective information regarding the tolerability and efficacy of endocrine therapy (ET) alone and in combination with targeted agents in older patients in the metastatic setting is limited. This review summarizes available trial data in this population. We searched PubMed for Phase 2 or 3 trials with age-stratified patient cohorts (≥ 65 vs. < 65 years in most studies) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer treated with ET ± targeted agents. We identified 19 studies reporting 10 clinical trials. Efficacy was similar in age-stratified subsets. There was a reduced disease progression risk for ET + everolimus, palbociclib, or ribociclib versus ET alone. In the first-line setting, median progression-free survival (mPFS) in older patients was 8.5, 26.2 months, and not reached with letrozole + temsirolimus, palbociclib, and ribociclib, respectively, and in younger patients was 9.0, 18.8 months, and not reached, respectively. In the second-line setting, older patients had mPFS of 6.8 and 9.9 months with everolimus + exemestane and palbociclib + fulvestrant, respectively, and younger patients had mPFS of 8.1 and 9.5 months, respectively. Tolerability was w...Continue Reading
References
Mar 29, 2005·The Oncologist·Matti S AaproMartine Extermann
May 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Benjamin D SmithThomas A Buchholz
Sep 24, 2010·Journal of the National Cancer Institute·Dejana BraithwaiteBette J Caan
Dec 14, 2011·The New England Journal of Medicine·José BaselgaGabriel N Hortobagyi
Aug 3, 2012·The New England Journal of Medicine·Rita S MehtaGabriel N Hortobagyi
Oct 20, 2012·British Journal of Cancer·L H LandM Ewertz
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffDaniel F Hayes
Aug 2, 2013·The Lancet Oncology·Stephen Rd JohnstonUNKNOWN SoFEA investigators
Oct 26, 2013·Advances in Therapy·Denise A YardleyHope S Rugo
Nov 26, 2013·Clinical Breast Cancer·Kathleen I PritchardMichael Gnant
Apr 30, 2014·Journal of the National Cancer Institute·Nadia HowladerKathleen A Cronin
Jul 30, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arti HurriaUNKNOWN Cancer and Aging Research Group
Sep 24, 2014·The Breast : Official Journal of the European Society of Mastology·F CardosoE Winer
Jun 2, 2015·The New England Journal of Medicine·Nicholas C TurnerUNKNOWN PALOMA3 Study Group
Oct 28, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J O'ShaughnessyS Johnston
Mar 8, 2016·The Lancet Oncology·Massimo CristofanilliDennis Slamon
Jun 29, 2016·Breast Cancer Research : BCR·Richard S FinnDennis J Slamon
Nov 3, 2016·The New England Journal of Medicine·Gabriel N HortobagyiJoyce O'Shaughnessy
Dec 14, 2016·The New England Journal of Medicine·Richard S FinnDennis J Slamon
Dec 20, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rachel A FreedmanArti Hurria
Jun 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George W SledgeAntonio Llombart-Cussac
Citations
Apr 30, 2019·Journal of the American Geriatrics Society·Allison MagnusonThuy Koll
Mar 15, 2019·Breast Cancer Research and Treatment·Peter A FaschingRamona Erber
May 7, 2020·PloS One·Jacob RinaldiGerard Manning
Apr 11, 2020·JAMA Network Open·Scott ParsonsVinay Prasad
Aug 31, 2018·Oncotarget·Marina CazzanigaValter Torri On Behalf Of The Eva Study Group
Jul 30, 2020·Current Oncology Reports·Nicolò Matteo Luca BattistiSupriya Mohile
May 9, 2019·Breast Cancer Research and Treatment·Marina Elena CazzanigaUNKNOWN NetworkER+
Jun 23, 2019·International Journal of Molecular Sciences·Elizabeth VargheseDietrich Büsselberg
Aug 24, 2018·Frontiers in Oncology·Z Ping LinElena S Ratner
Dec 5, 2019·ESMO Open·Ahmad AwadaChristoph Zielinski
May 28, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicolò Matteo Luca BattistiAlistair Ring
Feb 2, 2022·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·M D Torregrosa-MaicasR Gironés-Sarrió